20
Participants
Start Date
January 3, 2020
Primary Completion Date
December 31, 2030
Study Completion Date
December 31, 2030
LY3884961
Participants will receive a single dose of LY3884961, administered intra-cisterna magna
Methylprednisolone
6 IV pulses administered as concomitant medication over 3 months
Sirolimus
Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
COMPLETED
Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York
ACTIVE_NOT_RECRUITING
Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York
COMPLETED
PPD, 100 West Gore Street, Suite 202, Orlando
COMPLETED
Sheba Medical Center, Tel Hashomer, Ramat Gan
NOT_YET_RECRUITING
Mayo Clinic, 200 First Street SW, Rochester
ACTIVE_NOT_RECRUITING
Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago
COMPLETED
Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv
NOT_YET_RECRUITING
Mayo Clinic, 13400 E. Shea Boulevard, Scottsdale
COMPLETED
Shaare Zedek Medical Center, 12 Shmuel Biet Street, Jerusalem
COMPLETED
Hadassah Medical Center, Hadassah Ein Kerem, Dept. of Neurology, P.O. Box 12000, Jerusalem
RECRUITING
Esperanza Clinical, 25220 Hancock Avenue, Murrieta
RECRUITING
Rocky Mountain Clinical Research - CenExel - PPDS, 701 East Hampden Avenue Suite 510, Englewood
RECRUITING
K2 Medical Research, 101 Southhall Lane, Suite 150, Maitland
RECRUITING
Hospital of the University of Pennsylvania, 330 S. 9th Street, Philadelphia
Lead Sponsor
Eli Lilly and Company
INDUSTRY
Prevail Therapeutics
INDUSTRY